Sign In
Buy NXTC
$3.15
-0.250 (-7.35%)
At Close: Jun 03, 2026
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against NextCure Inc.
12:00am, Tuesday, 22'nd Sep 2020
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against NextCure, Inc.
What's Next For NextCure
02:03pm, Monday, 24'th Aug 2020
Today, we look at a small biotech concern that has entered 'Busted IPO' territory after a recent trial setback.
NextCure Reports Second Quarter 2020 Financial Results
08:03pm, Thursday, 06'th Aug 2020
BELTSVILLE, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
Reflecting on NextCure's (NASDAQ:NXTC) Share Price Returns Over The Last Year
06:47pm, Wednesday, 05'th Aug 2020
Taking the occasional loss comes part and parcel with investing on the stock market. And unfortunately for NextCure...
NextCure to Present at BTIG Virtual Biotechnology Conference
12:05pm, Wednesday, 05'th Aug 2020
BELTSVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
Will NextCure, Inc. (NXTC) Report Negative Q2 Earnings? What You Should Know
04:31pm, Monday, 03'rd Aug 2020
NextCure, Inc. (NXTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vident Investment Advisory LLC Buys 26,730 Shares of NextCure Inc (NASDAQ:NXTC)
06:54am, Monday, 03'rd Aug 2020
Vident Investment Advisory LLC lifted its position in NextCure Inc (NASDAQ:NXTC) by 94.3% during the second quarter, Holdings Channel reports. The institutional investor owned 55,077 shares of the com
NextCure (NASDAQ:NXTC) Shares Gap Down on Analyst Downgrade
08:24pm, Thursday, 16'th Jul 2020
NextCure Inc (NASDAQ:NXTC) gapped down prior to trading on Tuesday after BTIG Research lowered their price target on the stock from $61.00 to $27.00. The stock had previously closed at $3.55, but open
Scott+Scott Attorneys at Law LLP Announces Investigation into NextCure, Inc. (NXTC)
03:45pm, Wednesday, 15'th Jul 2020
Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, is investigating whether NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC)
Osmotica's FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma
11:57am, Monday, 13'th Jul 2020
Osmotica gets FDA approval for Droopy Eyelid Treatment. NextCure advances solid tumor trial of NC410.
BELTSVILLE, Md., July 13, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.04%
12:00am, Monday, 13'th Jul 2020
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.04%
NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors
08:05pm, Tuesday, 07'th Jul 2020
NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
Legal & General Group Plc Decreases Position in NextCure Inc (NASDAQ:NXTC)
04:52am, Monday, 06'th Jul 2020
Legal & General Group Plc lessened its holdings in NextCure Inc (NASDAQ:NXTC) by 18.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange C
NextCure Inc (NASDAQ:NXTC) Shares Sold by JPMorgan Chase & Co.
04:04am, Sunday, 05'th Jul 2020
JPMorgan Chase & Co. lowered its stake in shares of NextCure Inc (NASDAQ:NXTC) by 65.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange
